Singapore markets closed

Straits Times Index
3,426.47
-3.98(-0.12%)
Nikkei
37,667.41
-202.10(-0.53%)
Hang Seng
17,021.31
+16.34(+0.10%)
FTSE 100
8,285.71
+99.36(+1.21%)
Bitcoin USD
67,895.87
+2,204.32(+3.36%)
CMC Crypto 200
1,375.05
+44.44(+3.34%)

Relay Therapeutics, Inc. (RLAY)

NasdaqGM - NasdaqGM Real-time price. Currency in USD

Add to watchlist

8.94

-0.12

(-1.32%)

At close: 04:00PM EDT

9.11

+0.17

(+1.90%)

After hours:

05:49PM EDT

Trade prices are not sourced from all markets

All

Simply Wall St.
We're Not Very Worried About Relay Therapeutics' (NASDAQ:RLAY) Cash Burn Rate
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
GlobeNewswire
Relay Therapeutics Discloses Three New Programs at New Program & Platform Event
3 new programs include 2 genetic disease programs – vascular malformations & Fabry disease – & 1 precision oncology program – NRAS-specific inhibitor Cash guidance remains unchanged, and is expected to fund operations into second half of 2026 Relay Therapeutics to host webcast event today, June 6, at 8:00 a.m. ET CAMBRIDGE, Mass., June 06, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combi
GlobeNewswire
Relay Therapeutics Announces Clinical Trial Collaboration with Pfizer to Evaluate Atirmociclib in Combination with RLY-2608
Initial triplet combination of RLY-2608 + atirmociclib + fulvestrant to be evaluated in patients with PI3Kα-mutated HR+/HER2- metastatic breast cancer; initiation planned by end of 2024CAMBRIDGE, Mass., June 05, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced a clinical trial collaboration with Pfizer Inc. (NY